Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.

Aratari, A., Bossa, F., Cappello, M., Cassinotti, A., Chiriatti, A., Fiorino, G., et al. (2017). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). DIGESTIVE AND LIVER DISEASE, 49(4), 338-358 [10.1016/j.dld.2017.01.141].

Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Cappello M.;Formica V.;Onali S.;Sarmati L.;Biancone L.;Calabrese E.;Latella G.;Orlando A.;Petruzziello C.;
2017-01-01

Abstract

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.
2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/12
Settore MEDS-10/A - Gastroenterologia
English
Guidelines; Inflammatory bowel disease; Medical treatments; Safety; Adrenal Cortex Hormones; Aminosalicylic Acid; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Therapy, Combination; Female; Humans; Inflammatory Bowel Diseases; Italy; Mercaptopurine; Methotrexate; Pregnancy; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Necrosis Factor-alpha; Evidence-Based Medicine
Aratari, A., Bossa, F., Cappello, M., Cassinotti, A., Chiriatti, A., Fiorino, G., et al. (2017). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). DIGESTIVE AND LIVER DISEASE, 49(4), 338-358 [10.1016/j.dld.2017.01.141].
Aratari, A; Bossa, F; Cappello, M; Cassinotti, A; Chiriatti, A; Fiorino, G; Formica, V; Guidi, L; Losco, A; Mocciaro, F; Onali, S; Pastorelli, L; Pica...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
dld 2020.pdf

solo utenti autorizzati

Descrizione: published
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 589.79 kB
Formato Adobe PDF
589.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/396504
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 47
  • ???jsp.display-item.citation.isi??? ND
social impact